UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20

Clinical and translational science, 2024-04, Vol.17 (4), p.e13788-n/a

2024

Volltextzugriff (PDF)

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer

PloS one, 2021-07, Vol.16 (7), p.e0254765-e0254765

2021

Volltextzugriff (PDF)

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers

Current therapeutic research, 2020-01, Vol.93, p.100604, Article 100604

2020

Volltextzugriff (PDF)

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease

Neurobiology of disease, 2007-07, Vol.27 (1), p.67-76

2007

Volltextzugriff (PDF)

Engineering of Tooth-Supporting Structures by Delivery of PDGF Gene Therapy Vectors

Molecular therapy, 2004-04, Vol.9 (4), p.519-526

2004

Volltextzugriff (PDF)

Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers

Clinical therapeutics, 2014-02, Vol.36 (2), p.211-224

2014

Volltextzugriff (PDF)

The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies

Journal of controlled release, 2024-10, Vol.374, p.369-383

2024

Volltextzugriff (PDF)

Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery

Expert opinion on drug delivery, 2021-11, Vol.18 (11), p.1673-1685

2021

Volltextzugriff (PDF)

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration

The AAPS journal, 2022-10, Vol.24 (6), p.110-110, Article 110

2022

Volltextzugriff (PDF)

Recombinant human hyaluronidase PH20-mediated dermal spreading activity in mice is not altered by steroids, antihistamines, or salicylic acid

Drug metabolism and drug interactions, 2021-06, Vol.36 (2), p.155-163

2021

Volltextzugriff (PDF)

Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors

Human gene therapy, 2001-05, Vol.12 (7), p.783-798

2001

Volltextzugriff (PDF)

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

The AAPS journal, 2015-09, Vol.17 (5), p.1144-1156

2015

Volltextzugriff (PDF)

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

The AAPS journal, 2015-11, Vol.17 (6), p.1523-1524

2015

Volltextzugriff (PDF)

PH20 is not expressed in murine CNS and oligodendrocyte precursor cells

Annals of clinical and translational neurology, 2017-03, Vol.4 (3), p.191-211

2017

Volltextzugriff (PDF)

Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3375-3375

2013

Volltextzugriff (PDF)

Adenovirus Encoding Human Platelet-Derived Growth Factor-B Delivered in Collagen Exhibits Safety, Biodistribution, and Immunogenicity Profiles Favorable for Clinical Use

Molecular therapy, 2004-05, Vol.9 (5), p.699-711

2004

Volltextzugriff (PDF)

Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2672-2672

2012

Volltextzugriff (PDF)

Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism : Evidence for reduced toxicity and enhanced antitumor activity in mice

Cancer research (Chicago, Ill.), 1999-06, Vol.59 (11), p.2608-2614

1999

Volltextzugriff (PDF)

Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors

Human gene therapy, 2000, Vol.11 (1), p.191-204

2000

Volltextzugriff (PDF)

947. Effects of Natural Pre-Existing Humoral Immunity to AAV on Administration of AAV2-NTN to the Brain of Non-Human Primates

Molecular therapy, 2005-05, Vol.11 (S1), p.S366-S366

2005

Volltextzugriff (PDF)

Evaluation of Kawasaki Disease Risk-Scoring Systems for Intravenous Immunoglobulin Resistance

The Journal of pediatrics, 2011-05, Vol.158 (5), p.831-835.e3

2011

Volltextzugriff (PDF)

Comparison of Echocardiographic and Cardiac Magnetic Resonance Imaging Measurements of Functional Single Ventricular Volumes, Mass, and Ejection Fraction (from the Pediatric Heart Network Fontan Cross-Sectional Study)

The American journal of cardiology, 2009-08, Vol.104 (3), p.419-428

2009

Volltextzugriff (PDF)

Recommendations for Multimodality Assessment of Congenital Coronary Anomalies: A Guide from the American Society of Echocardiography: Developed in Collaboration with the Society for Cardiovascular Angiography and Interventions, Japanese Society of Echocardiography, and Society for Cardiovascular Magnetic Resonance

Journal of the American Society of Echocardiography, 2020-03, Vol.33 (3), p.259-294

2020

Volltextzugriff (PDF)

Plasma hyaluronan is a predictive marker for pegvorhyaluronidase alfa (PEGPH20; PVHA) response in a phase II study of pancreatic ductal adenocarcinoma (PDAC)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.404-404

2019

Volltextzugriff (PDF)

Influenza NA and PB1 Gene Segments Interact during the Formation of Viral Progeny: Localization of the Binding Region within the PB1 Gene

Viruses, 2016-08, Vol.8 (8), p.238

2016

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(53)

Sprache

Englisch
(53)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson’s disease

Engineering of Tooth-Supporting Structures by Delivery of PDGF Gene Therapy Vectors

Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers

The safety of recombinant human hyaluronidase PH20 in nonclinical models: An overview of toxicology, pharmacology, and impact of anti-PH20 antibodies

Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration

Recombinant human hyaluronidase PH20-mediated dermal spreading activity in mice is not altered by steroids, antihistamines, or salicylic acid

Matrix immobilization enhances the tissue repair activity of growth factor gene therapy vectors

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

PH20 is not expressed in murine CNS and oligodendrocyte precursor cells

Abstract 3375: Phase 1 pharmacodyamic activity of multiple-dose PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Adenovirus Encoding Human Platelet-Derived Growth Factor-B Delivered in Collagen Exhibits Safety, Biodistribution, and Immunogenicity Profiles Favorable for Clinical Use

Abstract 2672: Phase 1 pharmacokinetics (PK) & pharmacodynamics (PD) of PEGylated hyaluronidase PH20 (PEGPH20) in patients with solid tumors

Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism : Evidence for reduced toxicity and enhanced antitumor activity in mice

Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors

947. Effects of Natural Pre-Existing Humoral Immunity to AAV on Administration of AAV2-NTN to the Brain of Non-Human Primates

Evaluation of Kawasaki Disease Risk-Scoring Systems for Intravenous Immunoglobulin Resistance

Comparison of Echocardiographic and Cardiac Magnetic Resonance Imaging Measurements of Functional Single Ventricular Volumes, Mass, and Ejection Fraction (from the Pediatric Heart Network Fontan Cross-Sectional Study)

Plasma hyaluronan is a predictive marker for pegvorhyaluronidase alfa (PEGPH20; PVHA) response in a phase II study of pancreatic ductal adenocarcinoma (PDAC)

Influenza NA and PB1 Gene Segments Interact during the Formation of Viral Progeny: Localization of the Binding Region within the PB1 Gene

Suchergebnisse filtern